0001171843-23-004269.txt : 20230630 0001171843-23-004269.hdr.sgml : 20230630 20230629194308 ACCESSION NUMBER: 0001171843-23-004269 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230629 FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230629 FILER: COMPANY DATA: COMPANY CONFORMED NAME: XORTX Therapeutics Inc. CENTRAL INDEX KEY: 0001729214 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40858 FILM NUMBER: 231058948 BUSINESS ADDRESS: STREET 1: SUITE 2400 - 745 THURLOW STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 0C5 BUSINESS PHONE: 403-607-2621 MAIL ADDRESS: STREET 1: SUITE 2400 - 745 THURLOW STREET CITY: VANCOUVER STATE: A1 ZIP: V6E 0C5 6-K 1 f6k_062923.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2023

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33^rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX THERAPEUTICS INC.
		(Registrant)

Date:	June 29, 2023	By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT INDEX

99.1	Report on Voting Results

EX-99.1 2 exh_991.htm EXHIBIT 99.1

Exhibit 99.1

XORTX THERAPEUTICS INC.

Report of Voting Results
(Section 11.3 of National Instrument 51-102)

In accordance with section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, this report briefly describes the matters voted upon and the outcome of the votes at the Annual General and Special Meeting of Shareholders of XORTX Therapeutics Inc. (the “Company”) held on June 28, 2023 at the offices of the Company (the “Meeting”).

Election of Directors

The shareholders voted by way of proxy and the following nominees were elected as directors to serve until the next annual meeting of shareholders of the Company or until their successors are duly elected or appointed:

Director	Votes For		Votes Withheld
Allen Davidoff	3,432,152	52.65%	3,087,324	47.36%
William Farley	5,679,271	87.11%	840,205	12.89%
Anthony J. Giovinazzo	3,431,909	52.64%	3,087,567	47.36%
Ian Klassen	6,029,417	92.48%	490,059	7.52%
Raymond Pratt	5,929,174	90.95%	590,302	9.05%
Paul Van Damme	5,926,401	90.90%	593,075	9.10%

Appointment of Auditors

A resolution appointing Smythe LLP Chartered Professional Accountants, as auditor of the Company until the next annual meeting of shareholders and authorizing the directors of the Company to fix the auditor's remuneration was approved. Proxies were received as follows:

For the Motion:		7,359,275 (99.78%)
Withheld:		16,117 (0.22%)

Re-Approval of Stock Option Plan

A resolution re-approving and confirming the Company’s stock option plan as described in the management information circular dated May 16, 2023, including that the maximum number of common shares reserved for issuance under the stock option plan at any given time is equal to ten percent (10%) of the issued and outstanding common shares as at the date of grant of an option under the stock option plan, was approved. Proxies were received as follows:

For the Motion:		6,048,425 (94.33%)
Against:		363,453 (5.67%)

For additional information, please see the Company’s notice of meeting and information circular dated May 16, 2023 filed on SEDAR in connection with the Meeting.

DATED at Calgary, AB, June 29, 2023.

XORTX THERAPEUTICS INC.

/s/ Charlotte May

Charlotte May
Corporate Secretary